← Human Trials & Peer-Reviewed Studies
Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria
Plain-language guide to PMID 18613793 (2008): placebo-controlled randomized controlled trial study of Thymosin Alpha-1 in 120 patients.
Key Facts
- PMID
- 18613793
- Journal
- The Journal of infectious diseases
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Zhang Y et al. (9 authors)
- DOI
- 10.1086/590500
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Thymosin Alpha-1.
For both groups, flow cytometry was used to enumerate lymphocyte subsets, and ELISA was used to determine cytokine concentrations.
Why It Was Studied
The trial was registered with the Chinese State Food and Drug Administration (Peking Science and Technology Development Plan, 2002[641]), (registration number 2007Y0211).
Who Took Part
According to the abstract, 120 patients were involved.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
A total of 120 patients received a diagnosis of sepsis caused by infection with carbapenem-resistant bacteria and satisfied the study enrollment criteria.
Sixty patients received carbapenems combined with thymosin alpha(1) and ulinastatin (the CTU group), and the other 60 patients were treated with carbapenems and placebo (the CP group).
How the Study Was Run
The researchers set it up as a randomized, placebo-controlled and parallel-group study.
The patients were allocated by chance, so the Thymosin Alpha-1 group and the comparison group should start out alike.
The comparison arm used a placebo, so changes seen with Thymosin Alpha-1 could be set against what happens without it.
The Thymosin Alpha-1 group and the comparison group ran side by side rather than switching.
Prospective, randomized, parallel controlled clinical study.
What Was Measured
Topics PubMed links to this paper include Anti-Bacterial Agents, Bacteria, Carbapenems, Cholangitis, Drug Resistance, Multiple, Bacterial, Glycoproteins and Immunologic Factors.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and parallel-group study of Thymosin Alpha-1 in 120 patients.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2008 (The Journal of infectious diseases), a journal based in United States.
More context: the Thymosin Alpha-1 compound page, all human trials.
Our Notes on the Compound
Thymosin Alpha-1: An immune-modulating thymic peptide that recalibrates T-cell function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.